Current clinical perspectives on targeted therapy and immunotherapy for melanoma

Caroline Robert

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, from Institut Gustave Roussy, Villejuif, France, considers the impact of available and emerging targeted therapies and immunotherapies on the current treatment landscape in melanoma.

Share this video  
Similar topics
Related videos
2:03
Melanoma immunotherapy updates in 2016: clinical trials, developments and new survival data
Jeffrey Weber
2:15
ASCO 2016 highlights for immunotherapy
Hendrik-Tobias Arkenau
1:25
The use of mouse models in melanoma with brain metastases to test new therapies
Clemens Krepler
1:48
Influence of new immunotherapy checkpoint inhibitors in melanoma
James Larkin
1:34
Checkpoint blockers for skin cancer - effects in the periphery vs the central sites
Martin Mihm
Skin Cancer
ASCO 2015
Interview
30th May 2015
More from Caroline Robert
Immunotherapy and targeted therapies for melanoma
Metastatic melanoma: the CheckMate 067 and 069 trials
How can patients undergoing immunotherapy be supported?
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals